By Zachary Brennan
The FDA released new guidance to companies sponsoring oncology trials and focused on two important concepts — master protocols and expansion cohorts. Master protocol designs may incorporate design features from either basket and umbrella trials, FDA notes, offering the example of the NCI-MATCH trial as a master protocol with a complex trial design as it seeks to determine whether treating cancer based on these specific genetic changes is effective, no matter the cancer type.